Program
Lutetium-177
Also written as “[177Lu]Lu-NeoB”, “[177Lu]Lu-PSMA-617” and “Lutetium[177Lu] Oxodotreotide Injection”.
In Novartis's pipeline, Radioligand therapy target HER2
. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Neuroendocrine Tumors · Glioblastoma · Carcinoma, Non-Small-Cell Lung, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 108 open or running | phase 2since Dec 16, 2020 | Dec 16, 2020 | Dec 30, 2026phase 1 · NCT05870579 |
| Sinotau Pharmaceutical Group | 32 open or running | phase 3since Jul 5, 2022 | Jul 5, 2022 | Jun 1, 2027phase 3 · NCT06398444 |
| Bracco | 21 open or running | phase 2since May 20, 2022 | May 20, 2022 | none ahead |
| Sichuan Biokin Pharmaceutical | 22 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Dec 2027phase 1 · NCT07232407 |
| Affibody | 11 open or running | phase 1since Jun 23, 2025 | Jun 23, 2025 | Jan 1, 2027phase 1 · NCT07081555 |
| Alpha-9 Oncology USA | 11 open or running | phase 1since Jun 9, 2026 | Jun 9, 2026 | Dec 2028phase 1 · NCT07661641 |
| Cellbion | 11 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Apr 2029phase 1 · NCT07244393 |
| futurechem | 11 open or running | phase 2since Jun 10, 2022 | Jun 10, 2022 | none ahead |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since May 22, 2023 | May 22, 2023 | Dec 2026phase 3 · NCT05884255 |
| Philogen | 11 open or running | phase 1since Oct 10, 2024 | Oct 10, 2024 | May 31, 2028phase 1 · NCT06640413 |
| Spago Nanomedical AB | 11 open or running | phase 2since Dec 6, 2023 | Dec 6, 2023 | Dec 1, 2027phase 2 · NCT06184035 |
Also a collaborator on its studies: Merck, psi-cro, baili-bio-chengdu-pharmaceutical-co-ltd and medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Dec 16, 2020.
- Aug 25, 2023Phase 2 study in Prostatic NeoplasmsSinotau Pharmaceutical Group · NCT06081686 · 32 planned · China
- Dec 6, 2023Spago Nanomedical AB's first study: phase 2 study in Neoplasm MetastasisNew to Spago Nanomedical ABSpago Nanomedical AB · NCT06184035 · 90 planned · Australia
- Jan 17, 2024Phase 2 study in Breast NeoplasmsNovartis · NCT06247995 · 20 enrolled · United States, Australia, Canada and more
- Mar 4, 2024Phase 1 study in Metastatic Neuroendocrine Prostate CancerNovartis · NCT06379217 · 31 enrolled · United States, France, Germany and more
- May 1, 2024Phase 3 study in Advanced Neuroendocrine NeoplasmSinotau Pharmaceutical Group · NCT06398444 · 85 planned · China
- Jun 17, 2024Early phase 1 study in Prostatic NeoplasmsBracco · NCT06516510 · 17 enrolled · United States, Netherlands, Spain
- Aug 16, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNovartis · NCT06562192 · 162 planned · United States, Belgium, Canada and more
- Oct 10, 2024Philogen's first study: phase 1 study in FAPNew to PhilogenPhilogen · NCT06640413 · 56 planned · Italy
- Feb 25, 2025Phase 2 study in Prostatic NeoplasmsNovartis · NCT06881823
- Jun 23, 2025Affibody's first study: phase 1 study in Breast NeoplasmsNew to AffibodyAffibody · NCT07081555 · 21 planned · Sweden
- Nov 14, 2025Cellbion's first study: phase 1 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)New to CellbionCellbion · NCT07244393 · 30 planned · South Korea
- Nov 14, 2025Sichuan Biokin Pharmaceutical's first studies: 2 phase 1 studiesNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07232407, NCT07274852
- Jun 9, 2026Alpha-9 Oncology USA's first study: phase 1 study in Breast NeoplasmsNew to Alpha-9 Oncology USAAlpha-9 Oncology USA · NCT07661641 · 115 planned · Australia
- Jun 15, 2026Phase 1 study in Breast NeoplasmsNovartis · NCT07660055 · 156 planned · United States, Australia, Canada and more
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Gastroenteropancreatic Neuroendocrine TumorJiangsu HengRui Medicine · NCT05884255
- Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsNovartis · NCT05870579
- Jan 1, 2027Primary completion: phase 1 study in Breast NeoplasmsAffibody · NCT07081555
- Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT06247995
TargetBeta
“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Gallium-68 | Philogen | phase 3 | 17 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07660055Breast Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Novartis | May 24, 2032 | 156 |
| NCT07661641Breast Neoplasms · Australia | 1 | Recruiting | Alpha-9 Oncology USA | Dec 2028 | 115 |
| NCT07274852Lung Neoplasms · China | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2027 | 22 |
| NCT07244393Metastatic Castration-resistant Prostate Cancer (mCRPC) · South Korea | 1 | Recruiting | Cellbion | Apr 2029 | 30 |
| NCT07232407Digestive System Neoplasms · China | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2027 | 22 |
| NCT07081555Breast Neoplasms · Sweden | 1 | Recruiting | Affibody | Jan 1, 2027 | 21 |
| NCT06881823Prostatic Neoplasms | 2 | Withdrawn | Novartis | Mar 31, 2030 | 0 |
| NCT06640413FAP · Italy | 1 | Recruiting | Philogen | May 31, 2028 | 56 |
| NCT06562192Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 1 | Recruiting | Novartis | Jan 15, 2031 | 162 |
| NCT06516510Prostatic Neoplasms · United States, Netherlands, Spain | Early 1 | Terminated | Bracco | Aug 15, 2025 | 17 |
| NCT06398444Advanced Neuroendocrine Neoplasm · China | 3 | Recruiting | Sinotau Pharmaceutical Group | Jun 1, 2027 | 85 |
| NCT06379217Metastatic Neuroendocrine Prostate Cancer · United States, France, Germany and more | 1 | Active, not recruiting | Novartis | Oct 9, 2026 | 31 |
| NCT06247995Breast Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Novartis | Apr 14, 2027 | 20 |
| NCT06184035Neoplasm Metastasis · Australia | 2 | Recruiting | Spago Nanomedical AB | Dec 1, 2027 | 90 |
| NCT06081686Prostatic Neoplasms · China | 2 | Recruiting | Sinotau Pharmaceutical Group | Dec 31, 2027 | 32 |
| NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 220 |
| NCT05870579Breast Neoplasms · United States, China, France and more | 1 | Active, not recruiting | Novartis | Dec 30, 2026 | 28 |
| NCT05739942Glioblastoma · United States, France, Germany and more | 1 | Active, not recruiting | Novartis | Aug 10, 2027 | 42 |
| NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China | 2 | Active, not recruiting | Novartis | Dec 2, 2024 | 63 |
| NCT05670106Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China | 2 | Completed | Novartis | May 17, 2024 | 62 |
| NCT05459844Neuroendocrine Tumors · China | 3 | Completed | Sinotau Pharmaceutical Group | Jun 26, 2025 | 196 |
| NCT05458544Metastatic Castration-resistant Prostate Cancer · United States | 2 | Recruiting | futurechem | Jun 1, 2025 | 26 |
| NCT05413850Prostatic Neoplasms · United States, Belgium, Germany and more | 2 | Recruiting | Bracco | Aug 27, 2026 | 82 |
| NCT04711135Pheochromocytoma · United States, France, Poland and more | 2 | Active, not recruiting | Novartis | Mar 12, 2024 | 11 |
How it is read
Names in the registry
- “[177Lu]Lu-NeoB”, 4 entries
- “[177Lu]Lu-PSMA-617”, 3 entries
- “Lutetium[177Lu] Oxodotreotide Injection”, 2 entries
- “Lutetium [177Lu] BL-ARC001”, 2 entries
- “Phase I:[177Lu]Lu-XT033 Injection”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 9 studies
- Breast Neoplasms, 5 studies
- Neuroendocrine Tumors, 1 study
- Glioblastoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.